{ "id": "SQ-LIP-000022", "question": "What clinical criteria and stage/type classification systems are used to diagnose and grade lipedema, and how reliable are they?", "question_pt": "Quais critérios clínicos e sistemas de classificação de estágio/tipo são usados para diagnosticar e graduar o lipedema, e quão confiáveis são?", "phrasings": [ "How is lipedema diagnosed clinically, and which staging or type classification systems are used to grade it, and are they reliable?", "What are the clinical signs and the stage and type classification frameworks for identifying and grading lipedema, and how dependable are they?", "lipedema diagnostic criteria and stage type classification systems reliability", "When doctors check for lipedema, what signs and grading categories do they look at to figure out the type and stage, and can we trust those methods?" ], "phrasings_pt": [ "Como o lipedema é diagnosticado clinicamente e quais sistemas de classificação de estágio ou tipo são usados para graduá-lo, e eles são confiáveis?", "Quais são os sinais clínicos e os sistemas de classificação por estágio e tipo para identificar e graduar o lipedema, e qual a confiabilidade deles?", "critérios diagnósticos do lipedema e sistemas de classificação de estágio tipo confiabilidade", "Quando os médicos avaliam o lipedema, quais sinais e categorias de graduação eles observam para definir o tipo e o estágio, e dá para confiar nesses métodos?" ], "knowledge_state": "speculative", "tags": [ "Diagnosis", "Definition" ], "keywords": [ "clinical criteria", "staging", "type classification", "diagnostic reliability" ], "current_answer": "Based on currently indexed evidence, lipedema diagnosis is primarily clinical, resting on a recognized set of criteria: occurrence almost exclusively in (post-pubertal) women, bilateral symmetrical disproportionate fat deposition sparing the feet, pain/tenderness on palpation, easy bruising, negative Stemmer sign, and frequently family history and telangiectasias (SCR-LIP-000190, SCR-LIP-000193, SCR-LIP-000194). The most recent consensus guideline (S2k, 2024) states diagnosis requires disproportion plus concomitant symptoms such as pain, and that no instrument (duplex, ultrasound, MRI, lymphoscintigraphy, laboratory tests) can confirm lipedema—imaging serves only for differential diagnosis (SCR-LIP-000193). Two grading frameworks are commonly described: a morphological stage system (Stage I–III, or 1–4 in some cohorts: smooth skin with small nodules → irregular surface/liposclerosis → lobular deformation/peau d'orange) and a type/region classification (Schingale's 5 types, I hips/thighs through V lipo-lymphedema; type III 'hips to ankles' is commonly the most frequent, e.g., 74.7% in one cohort) (SCR-LIP-000189, SCR-LIP-000190, SCR-LIP-000194). Regarding reliability: clinical criteria perform well discriminatively—a CART algorithm using bruising, body disproportion, and non-swollen feet classified lipedema versus lymphedema with 100% accuracy (SCR-LIP-000190), and a simplified self-applied screening questionnaire derived from these criteria achieved AUC 0.86–0.91 against expert diagnosis (SCR-LIP-000188). However, the staging systems specifically are repeatedly flagged as weak: the S2k guideline recommends morphological staging NOT be used as a severity measure and that the 'nodular' criterion not be used for diagnosis (SCR-LIP-000193); the Wold-1951-based staging is argued to be insufficient for the disease's heterogeneity and in need of revision (SCR-LIP-000192, low-grade); and stage/type show no significant association with objective severity markers such as lymphoscintigraphic grade (SCR-LIP-000189) or DXA fat indices (SCR-LIP-000187). Multiple sources also caution that the underlying clinical criteria themselves may be subjective and not always reliable (SCR-LIP-000187). Proposed objective adjuncts have promising diagnostic accuracy but limited reliability validation: DXA leg-fat/total-fat index (AUC ~0.90, the only index discriminating across all BMI strata), pretibial ultrasound thickness (cutoffs 11.6–11.8 mm, sensitivity 0.77–0.79, specificity 0.92–0.96), and bioimpedance spectroscopy distinguishing even stage-1 lipedema from controls; yet a systematic review of 13 assessment tools found protocols heterogeneous and poorly documented, with clinimetric reliability reported in only 2 studies—tissue dielectric constant ICC 0.935–0.937 at distal leg/ankle but 0.633 at foot dorsum, and MR/lymphangiography showing only fair-to-slight interradiologist agreement (Kappa 0.14–0.34) (SCR-LIP-000187, SCR-LIP-000191, SCR-LIP-000195).", "current_answer_pt": "Com base nas evidências atualmente indexadas, o diagnóstico de lipedema é primariamente clínico, baseando-se em um conjunto reconhecido de critérios: ocorrência quase exclusiva em mulheres (pós-púberes), deposição de gordura desproporcional bilateral e simétrica poupando os pés, dor/sensibilidade à palpação, formação fácil de hematomas, sinal de Stemmer negativo e frequentemente história familiar e telangiectasias (SCR-LIP-000190, SCR-LIP-000193, SCR-LIP-000194). A diretriz de consenso mais recente (S2k, 2024) afirma que o diagnóstico requer desproporção mais sintomas concomitantes como dor, e que nenhum instrumento (duplex, ultrassom, RM, linfocintilografia, exames laboratoriais) pode confirmar lipedema—a imagem serve apenas para diagnóstico diferencial (SCR-LIP-000193). Dois sistemas de graduação são comumente descritos: um sistema de estágios morfológicos (Estágio I–III, ou 1–4 em algumas coortes: pele lisa com pequenos nódulos → superfície irregular/lipoesclerose → deformação lobular/peau d'orange) e uma classificação por tipo/região (5 tipos de Schingale, I quadris/coxas até V lipo-linfedema; o tipo III 'quadris aos tornozelos' é comumente o mais frequente, ex.: 74,7% em uma coorte) (SCR-LIP-000189, SCR-LIP-000190, SCR-LIP-000194). Quanto à confiabilidade: os critérios clínicos têm bom desempenho discriminativo—um algoritmo CART usando hematomas, desproporção corporal e pés não inchados classificou lipedema versus linfedema com 100% de acurácia (SCR-LIP-000190), e um questionário de triagem autoaplicável simplificado derivado desses critérios alcançou AUC 0,86–0,91 contra o diagnóstico especializado (SCR-LIP-000188). No entanto, os sistemas de estadiamento especificamente são repetidamente apontados como frágeis: a diretriz S2k recomenda que o estadiamento morfológico NÃO seja usado como medida de gravidade e que o critério 'nodular' não seja usado para diagnóstico (SCR-LIP-000193); o estadiamento baseado em Wold-1951 é argumentado como insuficiente para a heterogeneidade da doença e necessitando revisão (SCR-LIP-000192, baixo grau); e estágio/tipo não mostram associação significativa com marcadores objetivos de gravidade como grau linfocintilográfico (SCR-LIP-000189) ou índices de gordura por DXA (SCR-LIP-000187). Múltiplas fontes também alertam que os próprios critérios clínicos podem ser subjetivos e nem sempre confiáveis (SCR-LIP-000187). Adjuntos objetivos propostos têm acurácia diagnóstica promissora mas validação de confiabilidade limitada: índice gordura-perna/gordura-total por DXA (AUC ~0,90, o único índice a discriminar em todas as faixas de IMC), espessura ultrassonográfica pré-tibial (cortes 11,6–11,8 mm, sensibilidade 0,77–0,79, especificidade 0,92–0,96) e espectroscopia de bioimpedância distinguindo até lipedema estágio 1 de controles; contudo uma revisão sistemática de 13 ferramentas de avaliação encontrou protocolos heterogêneos e mal documentados, com confiabilidade clinimétrica relatada em apenas 2 estudos—constante dielétrica tecidual ICC 0,935–0,937 na perna distal/tornozelo mas 0,633 no dorso do pé, e RM/linfangiografia mostrando apenas concordância inter-radiologista de razoável a fraca (Kappa 0,14–0,34) (SCR-LIP-000187, SCR-LIP-000191, SCR-LIP-000195).", "major_uncertainty": "The single largest unresolved issue is that, while the clinical diagnostic criteria show strong discriminative performance against lymphedema/controls in specific cohorts (CART 100%, questionnaire AUC 0.86–0.91), there is NO high-grade evidence (no RCT, meta-analysis, or large multicenter validation with formal inter-rater/test-retest clinimetrics) establishing the reliability of either the core clinical criteria or the stage/type classification systems in routine practice; all supporting studies are graded moderate-to-very-low, the criteria are repeatedly described as subjective, and the staging systems explicitly lack correlation with objective severity markers, so neither diagnostic nor grading reliability can be considered established.", "version": "1.2", "created": "2026-05-31", "updated": "2026-05-31", "evidence_direction": { "supporting": 2, "contradicting": 0, "other": 7 }, "knowledge_freshness": { "pct": 56, "sources": 9, "newest": 2025, "oldest": 2012, "label": "mixed" }, "claims": [ { "id": "SCR-LIP-000187", "role": "refines", "statement": "In a study comparing lipedema patients to healthy controls, DXA body composition analysis showed the leg fat mass/total fat mass index achieved AUC=0.90 (sensitivity 0.95, specificity 0.73, cutoff 0.383) and was the only index to differentiate cases from controls across all BMI strata, but FM indices showed no significant correlation with disease stage, indicating they reflect the pathognomonic fat distribution rather than clinical progression; the study notes diagnosis is currently based almost exclusively on clinical criteria that may be subjective and not always reliable." }, { "id": "SCR-LIP-000188", "role": "refines", "statement": "A simplified 9-item self-applied screening questionnaire (derived from the validated QuASiL) based on clinical diagnostic criteria (post-pubertal women, bilateral symmetric fat deposit below the hip sparing feet, negative Stemmer and Godet signs, pain on palpation, spontaneous bruising) achieved diagnostic discrimination of AUC=0.912 for an individual 7-question predictive model and AUC=0.8615 for a total-score model against expert clinical diagnosis in 109 women (59 with lipedema, 50 without), with the item 'feeling something wrong in the legs' being most discriminative (OR=4.328)." }, { "id": "SCR-LIP-000189", "role": "context", "statement": "In a prospective cohort of 83 women diagnosed with lipedema using clinical criteria, lipedema was classified by clinical stage (most often stage 1, 39.8%) and type (most often type III, hips to ankles, 74.7%), and lymphoscintigraphic abnormality grade showed no significant association with clinical stage (p=0.142), type (p=0.505), Stemmer's sign (p=0.506), age, or BMI." }, { "id": "SCR-LIP-000190", "role": "supporting", "statement": "In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using three clinical variables—bruising, body disproportion, and non-swollen feet (cuffing sign)—classified patients with 100% accuracy; lipedema was characterized by symmetry (100%), spared feet (93.5%), pain (92%), bruising (90.6%), telangiectasias (89.9%), and family history (84.7%), and staged 1-4 (stage I 37.7%, II 34.8%, III 22.5%, IV 5.1%)." }, { "id": "SCR-LIP-000191", "role": "refines", "statement": "Bioimpedance spectroscopy of regional tissue fluid distinguished lipedema from Dercum's disease (lower leg/arm R0 ratio in lipedema, p<0.001) and detected stage 1 lipedema versus matched controls (leg/arm ratio R0 p=0.01, R1 p=0.007), with leg extracellular water increasing across lipedema stages (p=0.03), proposing BIS as an objective adjunct biomarker for diagnosis and staging." }, { "id": "SCR-LIP-000192", "role": "refines", "statement": "This systematic review of molecular and cellular lipedema studies argues that the current staging system based on Wold (1951) is insufficient for the disease's clinical heterogeneity and proposes its revision to incorporate comorbidities (obesity, lymphedema), pre-surgical weight, and family history." }, { "id": "SCR-LIP-000193", "role": "refines", "statement": "The S2k lipedema guideline defines lipedema as painful, disproportionate, symmetrical adipose distribution occurring almost exclusively in women, and states that diagnosis is clinical, requiring disproportion plus concomitant symptoms (pain), while morphological staging should NOT be used as a measure of severity, the 'nodular' criterion should not be used for diagnosis, and no instrument (duplex, ultrasound, MRI, lymphoscintigraphy, laboratory tests) can confirm lipedema (they serve only for differential diagnosis)." }, { "id": "SCR-LIP-000194", "role": "supporting", "statement": "This systematic review describes lipedema diagnosis as primarily clinical and outlines a 3-stage clinical staging system (Stage I normal skin with small palpable nodules; Stage II irregular surface with liposclerosis; Stage III lobular deformation with peau d'orange) plus Schingale's 5-type classification (I hips/thighs, II to knees, III to ankles, IV arms+legs, V lipo-lymphedema), with key differential signs (negative Stemmer, foot dorsum sparing) and noncontrast CT reported at 95% sensitivity and 100% specificity." }, { "id": "SCR-LIP-000195", "role": "refines", "statement": "A systematic review of 13 assessment tools (8 imaging, 5 clinical measurement) for quantifying lipedema limbs found highly heterogeneous and poorly documented protocols, with clinimetric reliability reported in only 2 studies: tissue dielectric constant showed high interrater reliability at the distal leg and ankle (ICC 0.935–0.937) but low at the foot dorsum (ICC 0.633), and MR/NCMRL showed only fair-to-slight interradiologist agreement (Kappa 0.14–0.34); DXA fat-distribution indices (AUC 0.91) and pretibial ultrasound subcutaneous thickness (cutoffs 11.6–11.8 mm, sensitivity 0.77–0.79, specificity 0.92–0.96) reported diagnostic performance." } ], "references": [ "DOI:10.1159/000527138", "DOI:10.1590/1677-5449.200114", "DOI:10.1016/j.remn.2018.06.008", "DOI:10.23736/s0392-9590.25.05207-1", "DOI:10.1089/lrb.2019.0011", "DOI:10.3390/jpm13010098", "DOI:10.1111/ddg.15513", "DOI:10.1111/j.1758-8111.2012.00045.x", "DOI:10.1089/lrb.2024.0102" ], "cite": "Scientific Claim Registry. What clinical criteria and stage/type classification systems are used to diagnose and grade lipedema, and how reliable are they?. SQ-LIP-000022 v1.2; 2026-05-31. https://scientificclaims.org/q/SQ-LIP-000022/v1.2.html", "versions": [ { "version": "1.2", "date": "2026-05-31", "url": "https://scientificclaims.org/q/SQ-LIP-000022/v1.2.html" }, { "version": "1.1", "date": "2026-05-31", "url": "https://scientificclaims.org/q/SQ-LIP-000022/v1.1.html" }, { "version": "1.0", "date": "2026-05-31", "url": "https://scientificclaims.org/q/SQ-LIP-000022/v1.0.html" } ], "url": "https://scientificclaims.org/q/SQ-LIP-000022.html", "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000022.html", "version_url": "https://scientificclaims.org/q/SQ-LIP-000022/v1.2.html", "license": "CC-BY-4.0", "disclaimer": "Evidence-bounded summary; not medical advice." }